Some of these complications, such as retinal detachment and loss of neural retinal cells, are related to the doses of anti-VEGF treatment given to the patient38; thus, lowering anti-VEGF doses while maintaining the therapeutic efficacy would be beneficial11. The gene discussed is VEGFA; the disease is retinal detachment.